Ocugen (OCGN) Competitors $0.98 -0.10 (-9.48%) (As of 03:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OCGN vs. LIFE, CRGX, MESO, CGEM, AUTL, SANA, REPL, RLAY, LENZ, and ADPTShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include aTyr Pharma (LIFE), CARGO Therapeutics (CRGX), Mesoblast (MESO), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Sana Biotechnology (SANA), Replimune Group (REPL), Relay Therapeutics (RLAY), LENZ Therapeutics (LENZ), and Adaptive Biotechnologies (ADPT). These companies are all part of the "biological products, except diagnostic" industry. Ocugen vs. aTyr Pharma CARGO Therapeutics Mesoblast Cullinan Therapeutics Autolus Therapeutics Sana Biotechnology Replimune Group Relay Therapeutics LENZ Therapeutics Adaptive Biotechnologies aTyr Pharma (NASDAQ:LIFE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Do institutionals and insiders hold more shares of LIFE or OCGN? 61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by company insiders. Comparatively, 4.3% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, LIFE or OCGN? aTyr Pharma has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.75, indicating that its stock price is 275% more volatile than the S&P 500. Do analysts prefer LIFE or OCGN? aTyr Pharma currently has a consensus price target of $25.50, indicating a potential upside of 0.00%. Ocugen has a consensus price target of $5.33, indicating a potential upside of 393.83%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LIFE or OCGN more profitable? aTyr Pharma's return on equity of -56.92% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -56.92% -43.87% Ocugen N/A -139.20%-87.85% Does the MarketBeat Community favor LIFE or OCGN? aTyr Pharma received 318 more outperform votes than Ocugen when rated by MarketBeat users. However, 69.33% of users gave Ocugen an outperform vote while only 59.86% of users gave aTyr Pharma an outperform vote. CompanyUnderperformOutperformaTyr PharmaOutperform Votes42259.86% Underperform Votes28340.14% OcugenOutperform Votes10469.33% Underperform Votes4630.67% Which has higher valuation and earnings, LIFE or OCGN? aTyr Pharma has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$350K0.00-$50.39M-$0.90N/AOcugen$6.04M51.47-$63.08M-$0.19-5.68 Does the media prefer LIFE or OCGN? In the previous week, Ocugen had 3 more articles in the media than aTyr Pharma. MarketBeat recorded 4 mentions for Ocugen and 1 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 equaled Ocugen'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOcugen beats aTyr Pharma on 8 of the 14 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$310.89M$3.20B$5.27B$8.82BDividend YieldN/A1.76%4.64%4.01%P/E Ratio-5.6812.58119.9616.14Price / Sales51.47325.241,328.52102.19Price / CashN/A147.8838.8934.14Price / Book6.755.265.825.78Net Income-$63.08M-$42.25M$118.30M$224.20M7 Day Performance13.77%15.71%4.08%4.17%1 Month Performance12.71%22.78%11.05%7.85%1 Year Performance181.03%53.27%39.14%28.75% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen0.8936 of 5 stars$0.98-9.5%$5.33+445.6%+184.5%$281.41M$6.04M-5.1565Gap UpLIFEaTyr Pharma1.8395 of 5 starsN/AN/AN/A$131.12M$350,000.00-2.1156Analyst ForecastCRGXCARGO Therapeutics1.9871 of 5 stars$21.20+4.1%N/AN/A$973.19MN/A-0.42116Positive NewsMESOMesoblast2.3685 of 5 stars$8.34-1.7%N/A+224.8%$952.26M$5.90M0.0080Gap UpCGEMCullinan Therapeutics1.9068 of 5 stars$15.92+0.9%N/A+58.0%$923.04M$18.94M-5.2030Upcoming EarningsInsider SellingNews CoverageAUTLAutolus Therapeutics2.9894 of 5 stars$3.34-4.6%N/A+9.8%$888.74M$1.70M-2.88330Upcoming EarningsSANASana Biotechnology2.1836 of 5 stars$3.76+2.7%N/A-20.1%$836.47MN/A-3.27328Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageREPLReplimune Group3.668 of 5 stars$12.02+1.0%N/A+12.7%$821.21MN/A-3.68210Upcoming EarningsRLAYRelay Therapeutics3.3559 of 5 stars$5.85+0.2%N/A-24.7%$783.26M$25.55M-2.32304Earnings ReportNews CoverageLENZLENZ Therapeutics0.9018 of 5 stars$28.43+1.8%N/AN/A$781.74MN/A0.00N/AAnalyst ForecastADPTAdaptive Biotechnologies3.0724 of 5 stars$5.26-0.9%N/A+16.8%$775.69M$170.28M-3.58709Earnings ReportNews CoverageGap Up Related Companies and Tools Related Companies aTyr Pharma Alternatives CARGO Therapeutics Alternatives Mesoblast Alternatives Cullinan Therapeutics Alternatives Autolus Therapeutics Alternatives Sana Biotechnology Alternatives Replimune Group Alternatives Relay Therapeutics Alternatives LENZ Therapeutics Alternatives Adaptive Biotechnologies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCGN) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
